Cowen's Line in the Sand
Executive Summary
Cowen's Dan LeMaitre, a leading device analyst, dropped coverage of Boston Scientific claiming that the company wasn't providing sufficient information for accurate valuations. The dispute calls into question an investor relations strategy one executive calls "seriously flawed."You may also be interested in...
UniQure Aiming To Be First With Hemophilia B Gene Therapy
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation
Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
Voluntary EU Joint Clinical Assessments ‘Risk Access To Medicines’
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports